The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients
| Autor: | Maaike de Boer, Maureen J.B. Aarts, Irene E. G. van Hellemond, Ingeborg J. H. Vriens, Joyce H.E. Roijen, Adri C. Voogd, Ron J. T. van Golde, Ashley J.R. De Bie, Vivianne C. G. Tjan-Heijnen |
|---|---|
| Přispěvatelé: | Promovendi ODB, Interne Geneeskunde, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Medische Oncologie (9), RS: GROW - R4 - Reproductive and Perinatal Medicine, MUMC+: CONC Patientenzorg OC (9), Obstetrie & Gynaecologie, MUMC+: MA Medische Staf Obstetrie Gynaecologie (9), RS: CAPHRI - R5 - Optimising Patient Care, Epidemiologie |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_treatment
Primary Ovarian Insufficiency chemotherapy Cohort Studies Follicle-stimulating hormone 0302 clinical medicine Obstetrics and gynaecology 030212 general & internal medicine Estradiol Letrozole Age Factors chemotherapy induced ovarian function failure Oncology PREMENOPAUSAL WOMEN Chemotherapy Adjuvant 030220 oncology & carcinogenesis TRIAL Female medicine.drug Research Paper Adult medicine.medical_specialty Anthracycline ovarian insufficiency Antineoplastic Agents Breast Neoplasms LETROZOLE INFERTILITY 03 medical and health sciences Breast cancer breast cancer medicine FERTILITY Humans PRESERVATION INDUCED AMENORRHEA TAMOXIFEN SUPPRESSION Proportional Hazards Models Retrospective Studies Gynecology Chemotherapy business.industry Proportional hazards model medicine.disease premenopausal patients ADJUVANT ENDOCRINE THERAPY Follicle Stimulating Hormone business Tamoxifen |
| Zdroj: | Oncotarget Oncotarget, 8(7), 11372-11379. Impact Journals LLC |
| ISSN: | 1949-2553 |
| Popis: | // Ingeborg J.H. Vriens 1 , Ashley J.R. De Bie 1 , Maureen J.B. Aarts 1 , Maaike de Boer 1 , Irene E.G. van Hellemond 1 , Joyce H.E. Roijen 1 , Ron J.T. van Golde 2 , Adri C. Voogd 1 , Vivianne C.G. Tjan-Heijnen 1 1 Department of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands 2 Department of Obstetrics and Gynaecology, Maastricht University Medical Center, Maastricht, The Netherlands Correspondence to: Vivianne C.G. Tjan-Heijnen, email: vcg.tjan.heijnen@mumc.nl Keywords: chemotherapy induced ovarian function failure, breast cancer, chemotherapy, ovarian insufficiency, premenopausal patients Received: July 20, 2016 Accepted: December 26, 2016 Published: January 05, 2017 ABSTRACT Purpose: To assess the incidence of chemotherapy-induced ovarian function failure (COFF) based on estradiol and follicle stimulating hormone (FSH) monitoring in premenopausal women with hormone-receptor positive breast cancer treated with second and third generation (neo-)adjuvant chemotherapy. Results: We identified 115 eligible women. Two years after start of chemotherapy, COFF was significantly more often present in women ≥ 40 years (85.6%) as compared to women < 40 years (8.7%). Only age was significantly associated with COFF two years after start of chemotherapy (HR 12.26; 95% CI 5.21–28.86). In 50% of the patients, premenopausal hormone levels were the first or only evidence of ovarian function recovery (OFR). Materials and Methods: We included all premenopausal women with hormone-receptor positive breast cancer treated with anthracycline-based chemotherapy, with or without taxanes, in our university hospital in the Netherlands in the years 2005-2013. Patients were 3-monthly monitored for ovarian function. Cox proportional hazards model was used to determine the predictive impact of various parameters on the occurrence of COFF. Conclusions: After second- or third generation (neo-)adjuvant chemotherapy, COFF was still present in 8.7% of patients < 40 years after two years. FSH and estradiol monitoring may be relevant for those in whom ovarian function suppression is considered an additional effective endocrine treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|